Cardiomyopathy

FDA headquarters
#Capricor Therapeutics #Cardiomyopathy #Duchenne muscular dystrophy #FDA

FDA rejects Capricor Therapeutics’ Duchenne muscular dystrophy drug 

The US Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee has voted that available evidence does not support the effectiveness of Capricor Therapeutics’ Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).  DMD is a rare and life-threatening disease for which no approved… Read More

#News #Regulatory

#Cardiomyopathy #Drug development #Drug discovery #FDA #HAYA Therapeutics #nHCM #RNA therapy #Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) #US Food and Drug Administration (FDA)

Treatment underway for nonobstructive hypertrophic cardiomyopathy 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).   The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May.  HTX-001 is a… Read More

#News